PPL freezes AAT program, restructures

PPL Therapeutics (LSE:PTH) and partner Bayer (FSE:BAYG; BAY) put their recombinant alpha-1 antitrypsin (recAAT) development program on hold

Read the full 180 word article

How to gain access

Continue reading with a
two-week free trial.